ClinicaliQ Trial Snapshot
- Structured Review: To Optimise Management and Prevent Harm in COPD — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07460154.
- What is being tested: A structured review intervention designed to optimise COPD management and prevent harm, focusing on reducing exacerbations and improving outcomes in patients experiencing sudden flare-ups of their condition.
- Patient eligibility overview: The trial includes people with COPD who experience exacerbations, encompassing both infection-triggered flare-ups and those occurring without an identifiable cause, representing the broader COPD population in UK healthcare settings.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Background: Chronic obstructive pulmonary disease (COPD) is a serious lung condition and the third leading cause of death worldwide. People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Flare-ups often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income. Sometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and…
Eligibility Snapshot
- COPD diagnosis documented in primary care records for at least 12 months. 2. Age 35 years or older 3. 3 or more prednisolone prescriptions in the past 12-months for ECOPD* 4. Capacity to give informed consent 5. Clinically stable at study entry (≥4 weeks following last ECOPD or other significant acute illness) * each prednisolone course separated by a minimum of 14 days from completion of the previous course.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.